Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | APEX1 | P27695 | 7/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | FABP2 | P12104 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201965 | 1.00 | AKR1C3 (0.54) | AKR1C3APEX1PTGS1MEN1KMT2A | |
| SCHEMBL7209266 | 0.86 | AKR1C3 (0.59) | AKR1C3APEX1 | |
| SCHEMBL7204993 | 0.83 | AKR1C3 (0.61) | AKR1C3APEX1MEN1KMT2A | |
| SCHEMBL6936533 | 0.80 | TRPA1 (0.55) | AKR1C3APEX1PTGS2LMNA | |
| SCHEMBL6936531 | 0.80 | TRPA1 (0.55) | AKR1C3APEX1PTGS2LMNA | |
| SCHEMBL4207637 | 0.80 | MGLL (0.48) | PTGS1PGRPDE4A | |
| SCHEMBL4207634 | 0.80 | MGLL (0.48) | PTGS1PGRPDE4A | |
| SCHEMBL11802318 | 0.79 | GLA (0.54) | AKR1C3PTGS1MEN1KMT2APTGS2 | |
| SCHEMBL11802307 | 0.79 | GLA (0.54) | AKR1C3PTGS1MEN1KMT2APTGS2 | |
| SCHEMBL2085780 | 0.78 | AKR1C3 (0.52) | AKR1C3APEX1PTGS1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2005092062-A2 | COMPOUNDS FOR NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | AKR1C3 570/4885APEX1 4527/4885PTGS1 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.